NanoValent Pharmaceuticals is a privately-held company, collaborating closely US-based and international academic and industry partners. We’re dedicated to creating novel treatment options designed to bring us closer to a potential cure for hard to treat cancers and hematological malignancies.
Our partners include:
- Children’s Hospital Los Angeles (CHLA)
- Translational Genomics Research Institute (TGen)